Quest Diagnostics (NYSE:DGX) Given New $260.00 Price Target at Mizuho

Quest Diagnostics (NYSE:DGX) had its target price raised by equities researchers at Mizuho from $235.00 to $260.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Mizuho’s target price suggests a potential upside of 12.39% from the stock’s current price.

DGX has been the subject of several other research reports. Weiss Ratings raised shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, July 9th. Evercore set a $225.00 price objective on shares of Quest Diagnostics in a research note on Tuesday, April 21st. Robert W. Baird lifted their price objective on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday. Jefferies Financial Group reissued a “buy” rating and set a $245.00 target price on shares of Quest Diagnostics in a research report on Thursday. Finally, Barclays lifted their price target on Quest Diagnostics from $230.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Quest Diagnostics presently has an average rating of “Moderate Buy” and an average target price of $231.73.

Quest Diagnostics Trading Up 1.5%

Shares of DGX traded up $3.43 during mid-day trading on Friday, reaching $231.33. 909,363 shares of the company were exchanged, compared to its average volume of 966,518. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.08 and a current ratio of 1.18. Quest Diagnostics has a 52 week low of $165.78 and a 52 week high of $237.78. The business has a 50 day simple moving average of $202.40 and a two-hundred day simple moving average of $197.37. The stock has a market capitalization of $25.61 billion, a PE ratio of 25.55, a PEG ratio of 2.50 and a beta of 0.58.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, beating the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a return on equity of 15.60% and a net margin of 9.07%.The company had revenue of $3.04 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter in the prior year, the company earned $2.62 EPS. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, analysts predict that Quest Diagnostics will post 10.72 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the completion of the transaction, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. This represents a 37.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.88% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

Several hedge funds have recently made changes to their positions in DGX. Assenagon Asset Management S.A. grew its stake in Quest Diagnostics by 346.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 24,949 shares of the medical research company’s stock valued at $4,329,000 after acquiring an additional 19,361 shares in the last quarter. Davis Selected Advisers boosted its holdings in Quest Diagnostics by 16.8% in the 4th quarter. Davis Selected Advisers now owns 1,589,883 shares of the medical research company’s stock valued at $275,895,000 after purchasing an additional 228,271 shares during the period. Capital Management Associates Inc purchased a new position in shares of Quest Diagnostics during the 4th quarter valued at $1,024,000. ANTIPODES PARTNERS Ltd increased its holdings in shares of Quest Diagnostics by 178.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 171,987 shares of the medical research company’s stock worth $29,847,000 after purchasing an additional 110,280 shares during the period. Finally, Advisors Capital Management LLC raised its position in shares of Quest Diagnostics by 5.4% in the fourth quarter. Advisors Capital Management LLC now owns 313,838 shares of the medical research company’s stock worth $54,460,000 after buying an additional 16,194 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

More Quest Diagnostics News

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics beat Wall Street estimates for Q2, reporting adjusted EPS of $3.12 and revenue of $3.04 billion, both above expectations, with revenue up 10.2% year over year. Article Title
• Positive Sentiment: The company raised its full-year 2026 outlook, now expecting adjusted EPS of $11.05 to $11.25 and revenue of $11.95 billion to $12.05 billion, signaling confidence in continued demand. Article Title
• Positive Sentiment: Management pointed to strong routine and preventive testing demand as a key growth driver, which supports the view that Quest can sustain momentum beyond the quarter. Article Title
• Neutral Sentiment: Robert W. Baird raised its price target to $255 from $236 while keeping a neutral rating, suggesting upside potential but not a full bullish upgrade. Article Title
• Neutral Sentiment: Several momentum-focused articles and “52-week high” commentary may keep trader interest elevated, but these pieces are largely follow-through on the earnings beat rather than new fundamentals. Article Title

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.